Lazard Asset Management
DGX icon

Lazard Asset Management’s Quest Diagnostics DGX Stock Holding History

Lazard Asset Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.52M Sell
48,586
-27,248
-36% -$5.29M 0.02% 433
2025
Q4 		$13.2M Buy
75,834
+72,228
+2,003% +$13.2M 0.02% 379
2025
Q3 		$687K Buy
3,606
+1,163
+48% +$206K ﹤0.01% 1255
2025
Q2 		$438K Sell
2,443
-684
-22% -$119K ﹤0.01% 1525
2025
Q1 		$529K Sell
3,127
-958
-23% -$157K ﹤0.01% 1391
2024
Q4 		$615K Sell
4,085
-4,572
-53% -$711K ﹤0.01% 1307
2024
Q3 		$1.34M Buy
8,657
+8,644
+66,492% +$1.29M ﹤0.01% 986
2024
Q2 		$1K Buy
+13
New +$1.78K ﹤0.01% 2136
2024
Q1 		– Sell
-740
Closed -$101K – 2117
2023
Q4 		$101K Sell
740
-261
-26% -$34.3K ﹤0.01% 1652
2023
Q3 		$121K Sell
1,001
-107
-10% -$14.3K ﹤0.01% 1558
2023
Q2 		$155K Sell
1,108
-1,166
-51% -$161K ﹤0.01% 1422
2023
Q1 		$320K Buy
2,274
+19
+0.8% +$2.72K ﹤0.01% 1205
2022
Q4 		$352K Sell
2,255
-141
-6% -$20.3K ﹤0.01% 1183
2022
Q3 		$293K Buy
2,396
+528
+28% +$69.5K ﹤0.01% 1190
2022
Q2 		$248K Sell
1,868
-256
-12% -$34.9K ﹤0.01% 1227
2022
Q1 		$289K Sell
2,124
-128,229
-98% -$17.9M ﹤0.01% 1196
2021
Q4 		$22.6M Sell
130,353
-15,303
-11% -$2.33M 0.02% 454
2021
Q3 		$21.2M Buy
145,656
+51,051
+54% +$7.47M 0.02% 459
2021
Q2 		$12.5M Sell
94,605
-5,835
-6% -$764K 0.01% 550
2021
Q1 		$12.9M Sell
100,440
-411
-0.4% -$50.6K 0.02% 506
2020
Q4 		$12M Sell
100,851
-27,351
-21% -$3.33M 0.02% 517
2020
Q3 		$14.7M Buy
128,202
+97,182
+313% +$11.5M 0.02% 441
2020
Q2 		$3.53M Buy
31,020
+30,998
+140,900% +$3.29M 0.01% 611
2020
Q1 		$1K Sell
22
-1,890
-99% -$196K ﹤0.01% 1550
2019
Q4 		$204K Buy
1,912
+310
+19% +$32.3K ﹤0.01% 912
2019
Q3 		$171K Sell
1,602
-105
-6% -$10.8K ﹤0.01% 932
2019
Q2 		$173K Buy
1,707
+1,602
+1,526% +$154K ﹤0.01% 1042
2019
Q1 		$9K Buy
105
+24
+30% +$2.08K ﹤0.01% 1101
2018
Q4 		$6K Sell
81
-16
-16% -$1.5K ﹤0.01% 987
2018
Q3 		$10K Sell
97
-7
-7% -$768 ﹤0.01% 998
2018
Q2 		$11K Sell
104
-11,535
-99% -$1.2M ﹤0.01% 977
2018
Q1 		$1.17M Sell
11,639
-48,307
-81% -$4.95M ﹤0.01% 696
2017
Q4 		$5.9M Buy
59,946
+21,840
+57% +$2.07M 0.01% 512
2017
Q3 		$3.57M Sell
38,106
-33,739
-47% -$3.58M 0.01% 574
2017
Q2 		$7.99M Sell
71,845
-6,363
-8% -$673K 0.02% 471
2017
Q1 		$7.68M Sell
78,208
-80,388
-51% -$7.66M 0.01% 503
2016
Q4 		$14.6M Buy
158,596
+24,494
+18% +$2.11M 0.03% 340
2016
Q3 		$11.3M Buy
134,102
+105,821
+374% +$8.89M 0.02% 391
2016
Q2 		$2.3M Buy
28,281
+25,926
+1,101% +$1.97M ﹤0.01% 614
2016
Q1 		$168K Buy
2,355
+156
+7% +$10.5K ﹤0.01% 800
2015
Q4 		$156K Sell
2,199
-5,079
-70% -$341K ﹤0.01% 853
2015
Q3 		$447K Buy
7,278
+4,920
+209% +$344K ﹤0.01% 713
2015
Q2 		$171K Buy
2,358
+1,252
+113% +$92.4K ﹤0.01% 864
2015
Q1 		$84K Buy
1,106
+233
+27% +$16.7K ﹤0.01% 937
2014
Q4 		$58K Buy
873
+34
+4% +$2.15K ﹤0.01% 1003
2014
Q3 		$50K Hold
839
– – ﹤0.01% 921
2014
Q2 		$49K Hold
839
– – ﹤0.01% 934
2014
Q1 		$48K Buy
839
+391
+87% +$21K ﹤0.01% 903
2013
Q4 		$23K Buy
+448
New +$26.6K ﹤0.01% 944

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Lazard Asset Management's DGX Position: Q1 2026 in Review

Lazard Asset Management reduced its Quest Diagnostics (DGX) stake by 36% in Q1 2026, selling an estimated $5.29M and leaving 48,586 shares worth $9.52M. The position accounts for 0.02% of the portfolio, ranked #433.

Lazard Asset Management first reported a position in DGX in Q4 2013 and has held it in 49 quarters since. The position peaked at $22.6M in Q4 2021. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Lazard Asset Management held 48,586 shares of Quest Diagnostics worth $9.52M as of Q1 2026.
  • Lazard Asset Management sold 27,248 Quest Diagnostics shares in Q1 2026, an estimated $5.29M.
  • Quest Diagnostics made up 0.02% of Lazard Asset Management's portfolio in Q1 2026, its #433 holding.
  • Lazard Asset Management first reported a position in Quest Diagnostics in Q4 2013 and has held it in 49 quarters since.
  • Lazard Asset Management's Quest Diagnostics position peaked at $22.6M in Q4 2021.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.